Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.25 | N/A | +9.88% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.25 | N/A | +9.88% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their pipeline and is optimistic about future opportunities. They did not provide specific guidance for the upcoming quarters.
Management expressed optimism about future developments despite the current loss.
They highlighted ongoing projects and potential upcoming milestones.
Krystal Biotech's earnings report shows a loss that was slightly better than expected, but the lack of revenue data raises concerns. The stock fell slightly by 0.41%, indicating that investors may be cautious about the company's future performance. Management's optimistic tone suggests they are focused on long-term growth despite current challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHART INDS INC
Feb 24, 2023